OptimizeRx annual gross margin
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
OptimizeRx's gross margin was 67.25% for fiscal 2025.
View full OptimizeRx company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 67.25% | +2.80 pp |
| 2024 | 2024-12-31 | 64.45% | +4.47 pp |
| 2023 | 2023-12-31 | 59.98% | −3741.66 pp |
| 2022 | 2022-12-31 | 3,801.64% | +3012.60 pp |
| 2021 | 2021-12-31 | 789.04% | +733.38 pp |
| 2020 | 2020-12-31 | 55.65% | −7.11 pp |
| 2019 | 2019-12-31 | 62.77% | +5.21 pp |
| 2018 | 2018-12-31 | 57.56% | +8.48 pp |
| 2017 | 2017-12-31 | 49.09% | −6.90 pp |
| 2016 | 2016-12-31 | 55.99% | +6.15 pp |
| 2015 | 2015-12-31 | 49.84% | −0.62 pp |
| 2014 | 2014-12-31 | 50.46% | −9.77 pp |
| 2013 | 2013-12-31 | 60.23% | −33.97 pp |
| 2012 | 2012-12-31 | 94.20% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | 74.75% | +6.61 pp |
| Q3 2025 | 2025-09-30 | 67.20% | +4.09 pp |
| Q2 2025 | 2025-06-30 | 63.83% | +1.61 pp |
| Q1 2025 | 2025-03-31 | 60.85% | −1.13 pp |
| Q4 2024 | 2024-12-31 | 68.15% | +5.26 pp |
| Q3 2024 | 2024-09-30 | 63.10% | +3.10 pp |
| Q2 2024 | 2024-06-30 | 62.22% | +5.59 pp |
| Q1 2024 | 2024-03-31 | 61.98% | +4.82 pp |
| Q4 2023 | 2023-12-31 | 62.89% | +0.44 pp |
| Q3 2023 | 2023-09-30 | 60.01% | −4.30 pp |
| Q2 2023 | 2023-06-30 | 56.63% | −2.37 pp |
| Q1 2023 | 2023-03-31 | 57.16% | +0.87 pp |
| Q3 2022 | 2022-09-30 | 62.45% | +3.41 pp |
| Q2 2022 | 2022-06-30 | 64.31% | +9.77 pp |
| Q1 2022 | 2022-03-31 | 59.00% | +6.62 pp |
| Q3 2021 | 2021-09-30 | 56.29% | −0.88 pp |
| Q2 2021 | 2021-06-30 | 59.04% | +0.47 pp |
| Q1 2021 | 2021-03-31 | 54.54% | −2.72 pp |
| Q4 2020 | 2020-12-31 | 52.38% | −8.23 pp |
| Q3 2020 | 2020-09-30 | 57.17% | −3.22 pp |
| Q2 2020 | 2020-06-30 | 58.57% | −3.08 pp |
| Q1 2020 | 2020-03-31 | 57.26% | −12.34 pp |
| Q4 2019 | 2019-12-31 | 60.61% | +19.31 pp |
| Q3 2019 | 2019-09-30 | 60.40% | −18.45 pp |
| Q2 2019 | 2019-06-30 | 61.65% | −28.03 pp |
| Q1 2019 | 2019-03-31 | 69.60% | +18.44 pp |
| Q4 2018 | 2018-12-31 | 41.30% | −3.39 pp |
| Q3 2018 | 2018-09-30 | 78.85% | +11.49 pp |
| Q2 2018 | 2018-06-30 | 89.68% | +33.72 pp |
| Q1 2018 | 2018-03-31 | 51.17% | +15.37 pp |
| Q4 2017 | 2017-12-31 | 44.69% | −17.26 pp |
| Q3 2017 | 2017-09-30 | 67.36% | +7.86 pp |
| Q2 2017 | 2017-06-30 | 55.96% | +4.19 pp |
| Q1 2017 | 2017-03-31 | 35.80% | −13.46 pp |
| Q4 2016 | 2016-12-31 | 61.95% | +8.43 pp |
| Q3 2016 | 2016-09-30 | 59.50% | +11.53 pp |
| Q2 2016 | 2016-06-30 | 51.77% | +3.50 pp |
| Q1 2016 | 2016-03-31 | 49.26% | +0.11 pp |
| Q4 2015 | 2015-12-31 | 53.52% | +2.91 pp |
| Q3 2015 | 2015-09-30 | 47.97% | +0.64 pp |
| Q2 2015 | 2015-06-30 | 48.26% | −0.56 pp |
| Q1 2015 | 2015-03-31 | 49.15% | −7.31 pp |
| Q4 2014 | 2014-12-31 | 50.61% | −34.60 pp |
| Q3 2014 | 2014-09-30 | 47.33% | −14.13 pp |
| Q2 2014 | 2014-06-30 | 48.83% | +13.88 pp |
| Q1 2014 | 2014-03-31 | 56.46% | −2.65 pp |
| Q4 2013 | 2013-12-31 | 85.21% | — |
| Q3 2013 | 2013-09-30 | 61.46% | — |
| Q2 2013 | 2013-06-30 | 34.95% | — |
| Q1 2013 | 2013-03-31 | 59.11% | — |
Over the last five reported fiscal years, OptimizeRx's gross margin increased from 55.65% to 67.25%, a change of +11.60 percentage points. The latest reported quarter, Q4 2025, shows 74.75%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review OptimizeRx filings at SEC.gov ↗